Access cutting-edge hiv infections treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Washington Dc location
Preparing your pre-screening questions…
Access hiv infections specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hiv infections treatment provided free
Check if you qualify for this hiv infections clinical trial in Washington Dc, DC
No-Cost Study Care
Local to Washington Dc
Convenient for DC residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This randomized Type 1 hybrid effectiveness-implementation trial (N=186) will evaluate the effectiveness and implementation of a peer-delivered problem solving and behavioral activation intervention for adherence to LAI-PrEP/ART ("Peer Activate-LAI") compared to enhanced treatment as usual (ETAU) for a largely Black, substance-using population living with or at high risk for HIV. Specific aims are to: Aim 1: Evaluate the effectiveness of Peer Activate-LAI over 12-months on: a) LAI-PrEP/ART adherence (primary; receipt of all 6 maintenance injections within 7-day window); and b) substance use (secondary; WHOASSIST, urine toxicology); and c) Explore the moderating role of SRD-related factors (exploratory) Aim 2: To evaluate the implementation of Peer Activate-LAI including feasibility, acceptability, fidelity, and adoption guided by RE-AIM and Proctor's model,12,13 assessed using mixed methods, including a rapid ethnographic assessment of how SRD-related factors may affect implementation. Aim 3: To evaluate the economic viability of Peer Activate-LAI, including a) cost of implementation and sustainment, and b) cost-effectiveness from multiple stakeholder perspectives. This study will inform a potentially scalable, cost-effective model for facilitating effective adherence to LAI formulations of PrEP/ART within Black, substance-using populations with multiple minority identities who to date have had limited support for improving LAI adherence for HIV treatment and prevention.
Sponsor: University of Maryland, Baltimore
Yes, this clinical trial (NCT06501781) has an active research site in Washington Dc, DC that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for hiv infections treatment options in Washington Dc, DC, this clinical trial (NCT06501781) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hiv infections specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all hiv infections clinical trials near you to find additional studies recruiting in your area.
See all hiv aids clinical trials recruiting in Washington Dc — not just this study.
Browse HIV AIDS Trials in Washington Dc →